-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Great news! A project from Shijiazhuang No.4 Pharmaceutical Group has been selected for the National List of Outstanding Smart Manufacturing Scenarios.
Category:
Time：2023-01-04
Recently, four government departments—the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation—released the list of demonstration smart manufacturing factories and outstanding scenarios for 2022. The product digital R&D and design project submitted by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was included in the list of outstanding smart manufacturing scenarios for 2022.
Recently, four government departments—the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation—released the list of demonstration smart manufacturing factories and outstanding scenarios for 2022. The product digital R&D and design project submitted by Shijiazhuang Sihua Pharmaceutical Co., Ltd. was included in the list of outstanding smart manufacturing scenarios for 2022.
Over the past two years, Shijiazhuang No.4 Pharmaceutical has been focusing on the cutting edge of technology and the market, leveraging digital R&D and design to tackle key “bottleneck” technologies. As a result, R&D efficiency has significantly improved, and the pace of intelligent industrialization has markedly accelerated, strongly promoting the company’s high-quality, innovation-driven development. In 2022, the number of approved and filed generic drugs with distinctive features from No.4 Pharmaceutical remained at an industry-leading level.
The head of the R&D Center at Shijiazhuang Fourth Pharmaceutical Company stated that digital transformation has become a trend in pharmaceutical companies’ product development and intelligent manufacturing. Every stage of pharmaceutical R&D—ranging from digitalization of research experiments and clinical data mining to real-world studies, drug safety, digital therapeutics, and market data insights—cannot do without in-depth big data analysis. Particularly under the application and analysis of artificial intelligence and big data, numerous R&D bottlenecks—including drug structure design, target discovery and validation, lead compound optimization, candidate drug development, and clinical studies—can be effectively addressed. Digital technologies will transform the way drugs are developed, enabling sophisticated biological simulations, significantly boosting the efficiency of drug development, effectively reducing R&D costs, and enhancing the efficiency of translating innovative findings into practical applications.
It is reported that, in order to implement the "14th Five-Year Plan for Intelligent Manufacturing Development," the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance, and the State Administration for Market Regulation are jointly launching the 2022 Pilot Demonstration Initiative for Intelligent Manufacturing. This initiative aims to select a group of outstanding intelligent manufacturing scenarios, build a number of demonstration intelligent manufacturing plants through an open bidding and leadership-selection approach, establish leading enterprises across various industries and fields, and promote high-quality development of intelligent manufacturing.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license